ESMO: GSK keeps the faith in anti-TIGIT plans; it's 'not always about being first'

Four months after the latest trial failure for Roche’s tiragolumab, GSK is still pushing ahead with its own anti-TIGIT inhibitor, bullish that plenty of opportunities remain for the next-gen therapy.